<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02746744</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2015-004116-38</org_study_id>
    <nct_id>NCT02746744</nct_id>
  </id_info>
  <brief_title>RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.</brief_title>
  <acronym>RIFUND-MS</acronym>
  <official_title>RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. A Randomized Phase 3 Study Comparing Rituximab With Dimethyl Fumarate in Early Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anders Svenningsson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized phase 3 study comparing Rituximab with Dimethyl Fumarate in early&#xD;
      Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomised phase 3 study comparing a novel treatment protocol of&#xD;
      Rituximab with a present first line disease modifying drug regarding both clinical,&#xD;
      radiological and biochemical parameters. This will be measured via clinical investigations,&#xD;
      MRI and Cerebrospinal fluid analyses. Each patient will have one treating physician&#xD;
      responsible for all ongoing medical questions and decisions regarding continuation in the&#xD;
      study and one examining physician performing the blinded Expanded Disability Status Scale&#xD;
      examination and assessments of exacerbations. The coordinating nurse will administer the&#xD;
      study-related tests and administer the rituximab infusions. In order to keep the examining&#xD;
      physician blinded the patients receiving disease modifying drug will receive infusions with&#xD;
      sodium chloride solution at the same interval as the rituximab arm is receiving. In both&#xD;
      instances an opaque cover bag will shield the content of the infusion solution. In this case&#xD;
      the examining physician will not be able to identify rituximab patients in case of accidental&#xD;
      meetings on the neurology unit.&#xD;
&#xD;
      Randomisation will be performed via a randomisation module in the national Swedish MS&#xD;
      registry. The patients will be randomised in a 1:1 ratio and receive their treatments in&#xD;
      accordance with clinical practice. Thus, the study will mimic the real-life situation in&#xD;
      which the treatments will be administered which involves both positive and negative&#xD;
      consequences. As positive consequence the result of the study will have a high degree of&#xD;
      validity in relation to expected outcome in clinical practice. As negative consequence there&#xD;
      may be psychological effects of knowing which medication one is receiving. Since both drugs&#xD;
      probably are perceived as positive treatment options in MS today it is unlikely that there&#xD;
      will be a predominant placebo effect of either of the treatment options.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">August 2021</completion_date>
  <primary_completion_date type="Actual">July 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom of relapse</measure>
    <time_frame>Within 2 years</time_frame>
    <description>The relative risk of experiencing a relapse during the two-year period for either compound.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of Mabthera/Rituximab every 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dimethyl Fumarate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Chloride solution</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham infusion with sodium chloride solution for the Tecfidera/Dimethyl Fumarate arm every 6 months (so that the examining physician will be blinded)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Infusion of Mabthera/Rituximab every 6 months</description>
    <arm_group_label>Rituximab</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimethyl fumarate</intervention_name>
    <description>Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.</description>
    <arm_group_label>Dimethyl Fumarate</arm_group_label>
    <arm_group_label>Sodium Chloride solution</arm_group_label>
    <other_name>Tecfidera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride solution</intervention_name>
    <description>Placebo/Sham infusion every 6 months so that the examining physician (blinded) should not know which patient gets Mabthera or Tecfidera</description>
    <arm_group_label>Dimethyl Fumarate</arm_group_label>
    <arm_group_label>Sodium Chloride solution</arm_group_label>
    <other_name>Sodium Chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Relapsing Remitting MS according to the 2017 revised McDonald cri-teria&#xD;
             27 OR one demyelinating episode in conjunction with at least one asympto-matic high&#xD;
             intensity T2 lesion with size and location compatible with MS.&#xD;
&#xD;
          -  Untreated OR treated with first-line injectables (interferon or glatiramer acetate)&#xD;
&#xD;
          -  Between the age of 18 and 50 years (inclusive) of age&#xD;
&#xD;
          -  No more than ten years of disease duration&#xD;
&#xD;
          -  During the previous year, clinical or radiological disease activity defined as at&#xD;
             least one of the following:&#xD;
&#xD;
               -  ≥ 1 relapse&#xD;
&#xD;
               -  ≥ 2 T2 lesions&#xD;
&#xD;
               -  ≥ 1 Gd+ lesions&#xD;
&#xD;
          -  Expanded Disability Status Scale: 0 - 5,5 (inclusive)&#xD;
&#xD;
          -  In fertile females, willing to comply with effective contraceptive methods. These&#xD;
             include birth control pills, surgical sterilization of patient or partner or&#xD;
             intrauterine device. Non-fertile women is defined as more than 12 months of amenorrhea&#xD;
             without an alternative medical cause or, in case of ambiguities, an follicle&#xD;
             stimulation hormone level in the postmenopausal range.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Progressive MS&#xD;
&#xD;
          -  Pregnant or lactating women: human chorionic gonadotropin (s-HCG) will be tested on&#xD;
             all women at screening, before each study-related infusion and in any situation where&#xD;
             there is a reason to suspect pregnancy during the trial, eg delayed menstrual period&#xD;
             more than five days above expected time.&#xD;
&#xD;
          -  Patients having contraindication for or otherwise not compliant with MRI&#xD;
             investigations&#xD;
&#xD;
          -  Simultaneous treatment with other immunosuppressive drugs&#xD;
&#xD;
          -  Active, severe infections Signs of infections are assessed before inclusion and each&#xD;
             study-related infusion through clinical examination and further evaluated by&#xD;
             laboratory and other relevant investigations in case of suspected ongoing infection.&#xD;
             Hepatitis serology (HBsAg and anti-HBc) will be evaluated before treatment onset.&#xD;
&#xD;
          -  Severe cardiac disorder, eg signs of congestive heart failure or coronary artery&#xD;
             disease. This will be evaluated through clinical assessment before inclusion.&#xD;
&#xD;
          -  Vaccination within 4 weeks of first dose of study medication.&#xD;
&#xD;
          -  Documented allergy or intolerance to any of the investigational products.&#xD;
&#xD;
          -  Severe psychiatric condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Svenningsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept.of Medicine, Sect.of Neurology, Danderyd Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Älvsborg Hospital</name>
      <address>
        <city>Borås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Falun Hospital</name>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gävle Hospital</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saghlgrenska Hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsingborg Hospital</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karlstad Hospital</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Halland Hospital Kungsbacka</name>
      <address>
        <city>Kungsbacka</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyköping Hospital</name>
      <address>
        <city>Nyköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capio StGöran Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danderyd hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fredrik Piehl</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Hospital Huddinge</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umeå University</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala Academiska Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Östersund Hospital</name>
      <address>
        <city>Östersund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2016</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Anders Svenningsson</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Dimethyl Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

